Three high-affinity binding sites for the GATA family of transcriptional regulators have been identified within the T-cell receptor beta-chain (TCRO) transcriptional enhancer, and their functional significance has been determined in an effort to understand the T-cell specificity of the enhancer more fully. One site, TE4, is important for activity of the enhancer in T cells. Neither site TE1 nor site TE2 can functionally replace a mutated TE4 site in T cells; however, the same protein, probably GATA-3, binds all three sites, as judged by electrophoretic mobility shift, oligonucleotide competition, and proteolytic clipping assays. These data suggest that additional proteins are critical for the ability of GATA-3 to activate the TCRi enhancer. In fibroblasts, the GATA sequence at site TE1 appears to bind a negative regulator. Since (47, 59) . The T-cell specificity of rearrangement and expression of the TCRao and -P genes is in part regulated at the level of transcription (2, 57). TCR, gene transcription appears to be primarily controlled by a T-cellspecific transcriptional enhancer located 3' of the C,B2 coding region (12, 21, 32, 43, 49) . Protein-binding sites have been identified in the TCRI enhancer, and the functional significance of some sites has been established (26); however, the molecular mechanisms which confer T-cell specificity are not well understood.
The ot3 T-cell receptor (TCR) is the major clonotypic antigen-specific receptor for T lymphocytes. Proper expression of TCR ot and ,B chains is critical for normal T-cell development, since the receptor is required for positive and negative selection of developing thymocytes and for activation of peripheral T cells (5, 55) . The genes encoding the ao and L chains are similar to immunoglobulin genes with respect to organization and DNA rearrangement (5, 55) . Furthermore, the same recombination machinery appears to be used for assembling TCR gene segments in T cells and immunoglobulin gene segments in B cells (47, 59) . The T-cell specificity of rearrangement and expression of the TCRao and -P genes is in part regulated at the level of transcription (2, 57) . TCR, gene transcription appears to be primarily controlled by a T-cellspecific transcriptional enhancer located 3' of the C,B2 coding region (12, 21, 32, 43, 49) . Protein-binding sites have been identified in the TCRI enhancer, and the functional significance of some sites has been established (26) ; however, the molecular mechanisms which confer T-cell specificity are not well understood.
GATA-3 is a transcription factor which has been shown to be important for determining the T-cell specificity of the TCRa and -8 genes (15, 18, 20, 29) . It is a member of the GATA family of transcription factors that recognize the consensus sequence WGATAR through a highly conserved C4 zinc finger domain (39) . In vertebrates, four GATA members, GATA-1 through GATA-4, have been identified, and it has been shown that these proteins have somewhat overlapping but distinctive patterns of expression (39) . The best-characterized member of this family is GATA-1, which is expressed in the erthyroid, megakaryocytic, mast cell, and germ cell lineages (7, 8, 30, 46, 51) . GATA-1 has been shown to regulate a number of erthryoid cell-specific genes and to be required for normal erythropoiesis (41) . Another family member, GATA-3, is the predominant GATA protein present in T cells, although high levels of GATA-3 are also detected in the developing central nervous system (15) . GATA-3 mRNA is detectable early in thymus ontogeny, being present at day 12.5 in developing embryos (26) . A number of enhancers that regulate T-cell-specific genes, including CD38 and the TCRat, -P, --y, and -8 genes, contain GATA sequences (26) . These observations have led to the suggestion that GATA-3, like GATA-1, may be important for regulating lineage-specific gene expression and restricting hematopoietic cells to a particular development fate.
The role of GATA-3 in determining the T-cell specificity of the TCRI enhancer is not known, although several regions with good matches to the GATA consensus are present within the enhancer (12, 29) . In this study, GATA-3-binding sites have been identified and their functional importance has been determined by mutational analysis. Three GATA-containing sites, TE1, TE2, and TE4, were shown to be recognized by proteins from crude T-cell nuclear extracts and to bind recombinant GATA-3 with high affinity. The GATA sequence at site TE4 is critical for the activity of the enhancer in T For o-phenathroline-copper (Op-Cu) nuclease footprinting, the reaction mixture described was increased 10-fold, and following electrophoresis, gels were treated with chemical endonuclease Op-Cu as previously described (23) . The gel was visualized by audioradiography, and the free and bound complexes were cut out and eluted from the gel (31). The DNA was then separated on a 6% sequencing gel with G and G+A ladders and visualized by autoradiography. Probes for EMSA and footprinting were generated from the murine TCRI enhancer. Probes were generated by 5' end labeling with T4 polynucleotide kinase (31) , end filling with the Klenow fragment of Escherichia coli polymerase (28) , or PCR using a kinase-treated oligonucleotide (22) . All probes were gel purified.
Site-directed mutagenesis. The TCRf3 enhancer was subcloned into pUC19, and site-specific mutations were generated by PCR using previously described protocols (24, 40) . Briefly, the procedure requires a single mutant primer and two flanking primers, which in this case annealed within the polylinker of pUC19. The oligonucleotides used in these experiments are shown in Table 1 
RESULTS
Three protein-binding sites within the TCR, enhancer contain a GATA consensus sequence and bind recombinant GATA-3 efliciently. Sequence analysis revealed several potential GATA-binding sites within the TCR,B enhancer. To determine which GATA sequences were recognized by nuclear proteins, EMSAs were performed with probes spanning the 800-bp PvuII-NcoI fragment previously shown to contain enhancer activity (32) . Nuclear extracts obtained from T cells, B cells, and fibroblasts were compared. Complexes TE1, TE2, TE4, and TE5 were unique to T-cell extracts ( Fig. 1) , although complexes with different mobilities bound to the same probes with non-T-cell extracts. Two additional complexes, TE3 and TE6, were observed in all extracts ( Fig. 1 and data not shown). When the six most prominent complexes were mapped by chemical nuclease footprinting, the consensus sequence for the GATA family of DNA-binding proteins, WGATAR, was observed in the sequences protected by the T-cell-specific complexes TE1, TE2, TE4, and TE5 (Fig. 1B) .
The possibility that sites TE1, TE2, TE4, and TE5 represent in vivo GATA-3-binding sites was further investigated. First, the ability of recombinant GATA-3 to bind the sites was tested by EMSA. As shown in Fig. 2A , probes that included sites TEl, TE2, TE4, and TE5 gave specific gel shift complexes in the presence of recombinant GATA-3. The lower-mobility complexes observed with the TE2 and TE4 probes probably represent degraded GATA-3 present in the crude bacterial extracts. In addition, oligonucleotides representing each site were used as unlabeled competitors in an EMSA in which recombinant GATA-3 was bound to Ta3, an established GATA-3-binding site from the TCRo enhancer (15) . TE1, TE2, and TE4 oligonucleotides competed very strongly for GATA-3 binding to Ta3 (Fig. 2B ), indicating that these sites bind recombinant GATA-3 with a high affinity. TE5 appears to bind recombinant GATA-3 with a lower affinity, since it was a VOL. 14, 1994 4288 HENDERSON ET AL. (A) EMSAs using nuclear extracts prepared from NIH 3T3 cells, the plasmacytoma cell lines P3XAg8.63 and S107, and the T-cell lines EL-4, RS4.2, and SL12.2. End-labeled probes generated from the PvuII-NcoI TCR, enhancer fragment were as follows: the TE1 probe is a 129-bp AluI-Hinfl fragment, the TE2 probe is a 139-bp Sau3A-EarI fragment, the TE4 probe is a 89-bp AluI-MboII fragment, and the TE5 probe is a 136-bp AluI-NcoI fragment. T-cell-specific complexes are indicated by solid arrows; the TE6 complex is indicated by the open arrow. (B) Summary of binding sites within the TCR,3 enhancer as determined by Op-Cu footprinting. T-cell-specific complexes are represented as hatched boxes; ubiquitous complexes are shown as stippled boxes. Potential GATA sequences are underlined. Binding sites described in previous studies (12, 49) that overlap the footprints are shown in parentheses. (C) Comparison of sequences from the footprinted sites of the murine TCR,B enhancer and known human TCR,B enhancer sequences (12, 43) . Differences in the murine sequence are shown below the human sequence. weak competitor. Finally, oligonucleotides containing a GATA-3 consensus sequence (Table 1) were used as unlabeled competitors to determine if the TE1, TE2, and TE4 complexes formed from T-cell nuclear extracts contained GATA-binding proteins. GATA oligonucleotides competed very efficiently for all three of the complexes (Fig. 2C) . Thus, GATA-binding protein is a component of the TE1, TE2, and TE4 EL-4 complexes. The T-cell specificity of these complexes is consistent with the possibility that the protein binding the sites is GATA-3 (Fig. 1A) . Taken together, the in vitro binding studies show that three sites, TE1, TE2, and TE4, are recognized by T-cell-specific proteins in nuclear extracts, contain GATA sequences, and bind recombinant GATA-3 efficiently. The T-cell specificity and ability of GATA oligonucleotides to compete for complexes TE1, TE2, and TE4 suggest that GATA-3 in T-cell nuclear extracts binds these sites.
The TE4 GATA sequence is required for TCROi enhancer activity in T cells; sites TE1 and TE2 are not functionally equivalent to site TE4. It is possible that the T-cell-specific activity of the TCR,B enhancer in vivo is mediated in part by GATA-3 binding at sites TE1, TE2, and TE4. Therefore, we designed experiments to determine if these three sites were important for TCRPi enhancer function and if they were functionally equivalent. Site-directed mutagenesis was performed on each site, using PCR (24, 40) (see Materials and Methods); the oligonucleotides used to generate the various mutations are shown in Table 1 . The ability of each of the mutant sites to bind protein is shown in Fig. 3 . Neither recombinant GATA-3 ( Fig. 3A) nor proteins present in EL-4 nuclear extracts (Fig. 3B) minimal effect on enhancer activity, decreasing activity of the element by 25% (Fig. 4) . Enhancer activity was not decreased further by a TE1 TE2 double mutation. However, the TE4 mutation had a significant effect on the TCRf enhancer function, resulting in an 85% decrease in the activity of the enhancer. Combined mutations were also tested in the same vector to determine whether sites TE1 or TE2 have subtle functions which would be revealed in the absence of another 
site(s). TCRP enhancers with combinations of mutated TE1
and TE4 sites or mutated TEl, TE2, and TE4 sites showed activity comparable to that of the enhancer with mutations in TE4 alone (Fig. 4) . Therefore, these data show that although several TCR3 sites can bind GATA-3, they are not functionally equivalent. The TE4 GATA sequence is required for full activity of the TCRI enhancer, whereas the TE1 and TE2 sites do not appear to be necessary, nor can they compensate functionally for the TE4 site.
T-cell nuclear proteins binding to sites TE1 and TE4 are biochemically indistinguishable. The experiments described above demonstrated that site TE4 is functionally distinct from sites TE1 and TE2. This functional difference could be caused by the presence of unique proteins in the TE4 complex. A more detailed biochemical analysis of the TE1 and TE4 complexes was performed to investigate this possibility.
Initially, EMSAs were performed with EL-4 nuclear extracts in the absence or presence of different competitors. The abilities of different sites to cross-compete for binding of nuclear proteins were tested by using oligonucleotides representing various binding sites. Figure 5A shows that the TE4 site competes completely for the TE1 and TE2 complexes. Moreover, TE1 and TE2 site oligonucleotides competed for binding of nuclear proteins to TE4 (data not shown). These results confirm the data obtained with use of GATA oligonucleotide competitors (Fig. 2C) (Fig. 1C) , and this may account for the observed differences in their abilities to bind CREB/ATF proteins. The protein-binding sites TE1 and TE4 were examined further in a proteolytic clipping assay (48) . Upon addition of Staphylococcus aureus V8 protease to the EMSA reactions, cleavage products binding both probes appear to be similar when the difference due to probe length is discounted (Fig.   5C ). Similar proteolytic products which retain binding ability indicate that identical or highly related proteins bind both sites. Thus, there is no evidence that the function of TE4 versus TE1 can be explained by differences in EL-4 nuclear proteins binding to the two sites in vitro. These data suggest that it is the context of TE4 that is different and that proteins bound at sites adjacent to the TE4 site may be required for its activity.
Site TE4 alone is not sufficient to function as a transcriptional enhancer. To determine directly if site TE4 could activate transcription in the absence of adjacent proteinbinding sites, a 25-bp region representing the TE4 site was multimerized and cloned 5' of the simian virus 40 early promoter lacking enhancer sequences in the pAlOLUC vector or the herpes simplex virus thymidine kinase promoter in the pBLCAT2 vector. Constructs with one, two, three, five, and six TE4 sites had no enhancer activity upon transfection into EL-4 cells (Fig. 6 and data not shown) . These data are apparently be due to differences in the cells used, differences in the promoter contexts of the multimers, or sequence differences between murine site TE4 and human site T12, possibly related to differences in their ability to bind CREB/ATF proteins. Our data show that although the GATA sequence within TE4 is necessary for enhancer function, the TE4 site alone is not sufficient to activate transcription of an enhancer-dependent promoter. These data further support the notion that transcription factors bound at other sites, possibly adjacent to TE4, are necessary for TE4-dependent activation. Site TE1 functions as a negative regulator of TCRI function in fibroblasts but not in B cells. The PvuI-NcoI enhancer construct used in the experiments described above has been previously shown to be T-cell specific (32) . Since tissue specificity of many enhancers, including T-cell-specific enhancers, is achieved by a combination of negative and positive elements (43, 57, 58) , we wished to determine if site TE1, TE2, or TE4 was important for keeping the enhancer activity low in fibroblasts or B cells. Therefore, the constructs containing single mutations were transfected into P3XAg8.63, a plasmacytoma B-cell line, and L cells, a fibroblast line. Consistent with previous data from this laboratory, the wild-type TCR,B enhancer was not active in the B-cell line (Fig. 7A) . In addition, none of the mutants showed significantly increased activity (Fig. 7A) . Negligible enhancer activity was also observed when L-cell fibroblasts were transfected with the wild-type enhancer or with the mutant TE2 and mutant TE4 enhancer constructs (Fig. 7B) . However, the TEI mutant enhancer showed modestly increased activity (in excess of threefold) in fibroblasts relative to wild-type or to the other mutant enhancers (Fig.  7B) . These results strongly suggest that a negative regulator present in fibroblasts binds to the TEI site. Since mutation of the GATA consensus within site TEl relieves repression, it seems likely that the negative regulator may be a member of the GATA family. The data further show that sites TE2 and TE4 cannot functionally replace site TEI for mediating the repressor activity. Finally, the data suggest that regulation of the TCRP3 enhancer is different in B cells and fibroblasts because the TEI mutation does not activate the enhancer in B cells.
DISCUSSION
This study examined the functional significance of GATA elements in determining the T-cell specificity the TCR3 enhancer; three important findings have emerged. First, only one of three high-affinity GATA-3-binding sites is critical for activation of the enhancer in T cells. Second, another GATA (12, 43, 49) . TE4 is the only site identified in this work that is within the minimal enhancer, and it corresponds to previously described sites Pe 1 and 3e2 in the murine enhancer and T,B2 in the human enhancer (12, 49) . Analysis of the TE4 GATA mutation confirms and extends previous deletional and mutational analyses in this region (12, 21, 29, 42, 49) . We examined the TE4 mutation within the context of an 800-bp enhancer fragment to determine whether other sites could compensate for TE4 function. This was particularly important since the TCR,B enhancer includes other GATA sequences, TEl and TE2, which bind recombinant GATA-3 with a high affinity and which are recognized by proteins from T-cell nuclear extracts. Our data show that TE4 is functionally distinct and that sites TEI and TE2 are not equivalent to TE4, since they were unable to compensate for the TE4 mutation. Although mutation of the GATA consensus VOL. 14, 1994 (19, 33) .
Our results further demonstrate that mutation of the TE4 GATA consensus sequence and loss of ability to bind recombinant GATA-3 correlate with loss of TE4 function, suggesting that GATA-3 is necessary for TE4-dependent activation in vivo. Four facts support this hypothesis: (i) GATA-3 is the only known GATA-binding protein present in T cells (15, 18, 37, 39) , (ii) TE4 binds recombinant GATA-3 strongly, (iii) GATA site oligonucleotides compete completely for the TE4 complex, and (iv) the TE4 complex is T cell specific, consistent with the T-cell-specific expression of GATA-3.
TEl and TE2 also bind recombinant GATA-3 and a tissuespecific protein complex from nuclear extracts. EMSAs with different competitor oligonucleotides suggest that these sites are also binding GATA-3. Furthermore, proteins binding to TE1 and TE4 appear to be similar, as judged from partial proteolysis. Thus (4, 10) .
There are potentially a number of proteins that could be required for GATA-3-dependent activation at the TE4 site. An obvious candidate was the CREB family of activators since the TE4 footprinted region includes sequences that match the consensus for a CRE which serves as a binding site for ATF/CREB family proteins (13, 16, 36) . CREs are found within the V,B promoter and the enhancers for TCRot, CD38 and CD2 (1, 9, 12, 25, 49 Negative regulation of the TCR, enhancer in non-T cells. The TCR,B enhancer is T-cell specific, having virtually undetectable activity in lineages such as fibroblasts and B cells (32, 49) . Although some of the T-cell specificity can be explained by the chromatin structure of the TCR3 enhancer in T cells and the presence in T cells of T-cell-specific activators such as GATA-3, it seems likely that negative regulators may also be required to keep the enhancer silent in non-T cells. Silencing elements have been identified in the TCRot and -,y enhancers, and a role for negative elements in the TCRP enhancer has been suggested in previous studies (17, 57, 58) .
When GATA site mutations were tested for activity in B cells and fibroblasts, the data showed that mutation of the TE1 site resulted in an increase in enhancer activity in fibroblasts but not in B cells, thus directly demonstrating negative regulation of the TCR,B enhancer. Mutation of sites TE2 and TE4 had no effect on enhancer activity in either cell type. The results suggest that a negative regulator binds the TE1 site in fibroblasts, although the identity of this protein is not currently known. EMSAs and chemical nuclease footprinting show a protein present in crude nuclear extracts from fibroblasts which binds TEl and TE4, generating complexes different in mobility and footprint patterns from the T-cell complexes (Fig.  1A and data not shown) . Since these complexes are also competed for with GATA oligonucleotides and abolished by mutation of the GATA consensus sequence (data not shown), the negative regulator may be a GATA family member. Although GATA family members have been demonstrated to act as positive factors, a recent study demonstrated that ectopic expression of GATA-2 could inhibit erthryoid differentiation, indicating that in certain situations, GATA proteins may act as negative regulators (3) . It is also possible that the GATA element overlaps a non-GATA-binding repressor element, similar to that proposed for the glycophorin B promoter (44) .
These data also reveal another functional difference between GATA sites, since TE4 cannot replace TE1 for negative regulation, even though TE1 and TE4 appear to bind indistinguishable proteins.
Our data also suggest that the mechanisms for negative regulation of the TCR,B enhancer are different in B cells and fibroblasts, since mutation of the TEl site increased enhancer activity in fibroblasts but not in B cells. It is interesting to speculate that this difference may be related to the need to control rearrangement of T-cell receptor and immunoglobulin genes. There is evidence that enhancer-dependent transcription in the immunoglobulin and T-cell receptor loci may target the V(D)J recombination machinery to the correct genes in B cells and T cells, respectively (59) . Thus, it may be that special mechanisms are necessary in B cells to silence TCR3 transcription to ensure that a-chain genes are not rearranged in B cells.
